ReviewOncotarget2015
Targeting the tumor microenvironment to enhance antitumor immune responses.
Review in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Article
- mRNA-LNP vaccination-based immunotherapy augments CD8NPJ vaccines · 2023Article
- Colorectal Cancer Immunotherapy: State of the Art and Future Directions.Gastro hep advances · 2023Article
- RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.The Journal of clinical investigation · 2021Article
- mRNA in cancer immunotherapy: beyond a source of antigen.Molecular cancer · 2021Review
- An Evaluation of the Use of Corticosteroids for the Management of Immune-Mediated Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.Journal of the advanced practitioner in oncology · 2021Article
- Implementing Logic Gates for Safer Immunotherapy of Cancer.Frontiers in immunology · 2021Review
- Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications.Frontiers in cell and developmental biology · 2021Review
- Review
- ST2 as checkpoint target for colorectal cancer immunotherapy.JCI insight · 2020Article
- Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells.Cancers · 2020Article
- Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).Advances in therapy · 2019Review
- Theranostics in immuno-oncology using nanobody derivatives.Theranostics · 2019Review
- Drug resistance and new therapies in colorectal cancer.World journal of gastroenterology · 2018Review
- miR-130a and miR-145 reprogram Gr-1Nature communications · 2018Article
- Towards superior dendritic-cell vaccines for cancer therapy.Nature biomedical engineering · 2018Article
- Synthetic immune niches for cancer immunotherapy.Nature reviews. Immunology · 2018Review
- Single-cell RNA sequencing reveals gene expression signatures of breast cancer-associated endothelial cells.Oncotarget · 2018Article
- Altered Toll-like receptor expression and function in HPV-associated oropharyngeal carcinoma.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of tumor-specific antigens and the immune responses directed against them has instigated the development of therapies to enhance antitumor immune responses. Most of these cancer immunotherapies are administered systemically rather than directly to tumors. Nonetheless, numerous studies have demonstrated that intratumoral therapy is an attractive approach, both for immunization and immunomodulation purposes. Injection, recruitment and/or activation of antigen-presenting cells in the tumor nest have been extensively studied as strategies to cross-prime immune responses. Moreover, delivery of stimulatory cytokines, blockade of inhibitory cytokines and immune checkpoint blockade have been explored to restore immunological fitness at the tumor site. These tumor-targeted therapies have the potential to induce systemic immunity without the toxicity that is often associated with systemic treatments. We review the most promising intratumoral immunotherapies, how these affect systemic antitumor immunity such that disseminated tumor cells are eliminated, and which approaches have been proven successful in animal models and patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.